Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 14/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | PTGIR | P43119 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.33 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9922602 | 0.97 | P2RY12 (0.39) | P2RY12PTGER3PTGER1PTGER4PTGER2 | |
| SCHEMBL9922792 | 0.90 | P2RY12 (0.48) | P2RY12PTGER3FBP1KIT | |
| SCHEMBL9922262 | 0.86 | P2RY12 (0.48) | P2RY12PTGER3FBP1KIT | |
| SCHEMBL9922600 | 0.83 | IKBKB (0.41) | P2RY12PTGER3PTGER1PTGER4PTGER2 | |
| SCHEMBL12161548 | 0.82 | P2RY12 (0.36) | P2RY12PTGER3PTGER1PTGER4PTGER2 | |
| SCHEMBL12161004 | 0.81 | P2RY12 (0.43) | P2RY12FBP1KIT | |
| SCHEMBL9922844 | 0.80 | P2RY12 (0.42) | P2RY12PTGER3FBP1KIT | |
| SCHEMBL12177235 | 0.80 | P2RY12 (0.37) | P2RY12KIT | |
| SCHEMBL9922603 | 0.80 | P2RY12 (0.39) | P2RY12PTGER3PTGER1PTGER4PTGER2 | |
| SCHEMBL9922077 | 0.79 | P2RY12 (0.47) | P2RY12FBP1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524721-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | P2RY12 18/4885PTGER3 97/4885PTGER1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.